A pahse 2 clinical study of levosimendan to treat patients with Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)

Trial Profile

A pahse 2 clinical study of levosimendan to treat patients with Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)

Planning
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2018

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2018 New trial record
    • 16 Jan 2018 According to a Tenax Therapeutics media release, this trial may initiate in third quarter of 2018. A pre-IND Meeting is scheduled with FDA to discuss development of levosimendan in PH-HFpEF in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top